Emerging role of pemetrexed in ovarian cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 12, 2009, Pages 1727-1735

  Tomao, Federica ^a   Panici, Pierluigi Benedetti ^a   Frati, Luigi ^a   Tomao, Silverio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Carboplatin; Chemotherapy; Cisplatin; Epithelial ovarian cancer; Overall survival; Pemetrexed; Recurrent disease; Response rate; Targeted therapies; Taxanes

Indexed keywords

CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLIC ACID; GEMCITABINE; METHOTREXATE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; RALTITREXED; TAXANE DERIVATIVE; TOPOTECAN; TRABECTEDIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLADDER CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG CHOICE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; MESOTHELIOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PLEURA MESOTHELIOMA; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTAMATES; GUANINE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 73349089623     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.141     Document Type: Review

References (84)

1. Jemal PA, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin. 57(1), 43-66 (2007).
2. Bookman MA. Developmental chemotherapy and management of recurrent ovarian cancer. J. Clin. Oncol. 21(Suppl.), 149s-167s (2003).
3. Cannistra SA. Cancer of the ovary. N. Engl. J. Med. 351, 2519-2529 (2004).
4. Armstrong D. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. The Oncologist 7, 20-28 (2007). Educational approach in the treatment of ovarian relapsed cancer.
5. Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J. Clin. Oncol. 10, 513-514 (1992).
6. Ozols R. Systemic therapy for ovarian cancer: current status and new treatments. Semin. Oncol. 33(Suppl.), S3-S11 (2006). Complete overview about the current and future treatment of ovarian cancer.
7. Salzberg M, Thurlimann B, Bonnefois H et al. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 68, 293-298 (2005).
8. Martin LP, Schilder RJ. Management of recurrent ovarian carcinoma: current status and future directions. Semin. Oncol. 36(2), 112-125 (2009).
9. Herzog TJ. The current treatment of recurrent ovarian cancer. Curr. Oncol. Rep. 8, 448-454 (2006).
10. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 16(2), 405-410 (1998).
11. Sehouli J, Stengel D, Oskay-Oezcelik G et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a Phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J. Clin. Oncol. 26(19), 3176-3182 (2008).
12. Meier W, du Bois A, Reuss A et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized Phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol. Oncol. 114(2), 199-205 (2009).
13. Mutch DG, Orlando M, Goss T et al. Randomized Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinumresistant ovarian cancer. J. Clin. Oncol. 25(19), 2811-2818 (2007).
14. Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J. Clin. Oncol. 26(6), 890-896 (2008).
15. Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol. 95(1), 1-8 (2004).
16. Piccart MJ, Green JA, Lacave AJ et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized Phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J. Clin. Oncol. 18(6), 1193-1202 (2000).
17. ten Bokkel Huinink W, Lane SR, Ross GA; International Topotecan Study Group. Long-term survival in a Phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann. Oncol. 15(1), 100-103 (2004).
18. Pfisterer J, Plante M, Vergote I et al.; AGO-OVAR; NCIC CTG; EORTC GCG. J. Clin. Oncol. 24(29), 4699-4707 (2006).
19. Parmar MK, Ledermann JA, Colombo N et al.; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/ AGO-OVAR-2.2 trial. Lancet 361(9375), 2099-2106 (2003).
20. Rothenberg ML, Liu PY, Wilczynski S et al. Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Gynecol. Oncol. 95(3), 506-512 (2004).
21. Bajetta E, Di Leo A, Biganzoli L et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J. Clin. Oncol. 14(9), 2546-2551 (1996).
22. Krasner CN, McMeekin DS, Chan S et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br. J. Cancer 97(12), 1618-1624 (2007).
23. Sessa C, De Braud F, Perotti A et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J. Clin. Oncol. 23(9), 1867-1874 (2005).
24. Rose PG, Fusco N, Fluellen L et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J. Clin. Oncol. 16, 1494-1497 (1998).
25. Bolis G, Scarfone G, Sciatta C et al. A Phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer. Gynecol. Oncol. 83, 477-480 (2001).
26. Pfisterer J, Vergote I, Du Bois A, Eisenhauer E; AGO-OVAR; NCIC CTG; EORTC GCG. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int. J. Gynecol. Cancer 15(Suppl. 1), 36-41 (2005).
27. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 15, 3987-3993 (1997).
28. Shih C, Chen VJ, Gosset LS et al. LY231514, a pyrrolo[2,3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 57, 1116-1123 (1997).
29. Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin. Cancer Res. 10, 4276s-4280s (2004).
30. Westerhof GR, Schornagel JH, Kathmann I et al. Carrier and receptor mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular structure and biological activity. Mol. Pharmacol. 48, 459-471 (1995).
31. Manegold C, Gatzemeier U, von Pawel J et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter Phase II trial. Ann. Oncol. 11, 435-440, (2000).
32. Shepherd FA, Dancey J, Arnold A et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92, 595-600 (2001).
33. Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22, 1589-1597 (2004). Innovative chemotherapeutic association in the second line of treatment of non-small-cell lung cancer.
34. Paz-Ares L, Ciruelos E, Garcia-Carbonero R et al. Pemetrexed in bladder, head and neck, and cervical cancers. Semin. Oncol. 29(Suppl. 18), 69-75 (2002).
35. Wu M, Gunning W, Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol. Biomarkers Prev. 8, 775-782 (1999).
36. Garin A, Manikhas A, Biakhov M et al. A Phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer. Breast Cancer Res. Treat. 110, 309-315 (2008).
37. Scagliotti GV, Kortsik C, Dark GG et al. Pemetrexed combined with oxaliplatin or carboplatin as front-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, Phase II trial. Clin. Cancer Res. 11, 690-696 (2005).
38. Goedhals L, van Wiyk AL, Smith BL et al. Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a Phase II single-agent trial. Int. J. Gynecol. Cancer 16, 1172-1178 (2006).
39. Miller DS, Blessing JA, Bodurka DC et al. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a Phase II study of the Gynecologic Oncology Group. Gynecol. Oncol. 110, 65-70 (2008).
40. Miller DS, Blessing JA, Krasner CN et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J. Clin. Oncol. 27(16), 2686-2691 (2009). Identification of a novel drug as an active single agent, in the chemotherapy of recurrent or persistent platinum-resistant ovarian cancer.
41. Vergote I, Calvert H, Kania M, Kaiser C, Zimmermann AH, Sehouli J. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur. J. Cancer 45(8), 1415-1423 (2009). Demonstration of the best scheduled dose of pemetrexed in the routine treatment of platinum-resistant ovarian cancer.
42. Gasent Blesa JM, Alberola Candel V, Provencio Pulla M, Esteban González E, Martín Algarra S. Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine. Clin. Transl. Oncol. 11(1), 35-40 (2009). Innovative chemotherapeutic association with two active agents (pemetrexed and gemcitabine) for the treatment of platinum-resistant ovarian cancer.
43. Matulonis UA, Horowitz NS, Campos SM et al. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J. Clin. Oncol. 26(35), 5761-5766 (2008). First clinical trial showing an interesting activity of pemetrexed in ovarian cancer.
44. Rinaldi DA, Burris HA, Dorr FA et al. Initial Phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J. Clin. Oncol. 13, 2842-2850 (1995).
45. McDonald AC, Vasey PA, Adams L et al. A Phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin. Cancer Res. 4, 605-610 (1998).
46. Rinaldi DA. Overview of phase I trials of multitargeted antifolate (MTA, LY231514). Semin. Oncol. 26(2 Suppl. 6), 82-88 (1999).
47. Rusthoven JJ, Eisenhauer E, Butts C et al. Multitargeted antifolate, LY231514, as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a Phase II study - National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 17, 1194-1199 (1999).
48. Sharma A, Johnson RD, Woodworth JM. Comparative human pharmacokinetics of MTA in three Phase I studies. Proc. Am. Soc. Clin. Oncol. 17, 235a (1998) (Abstract 900).
49. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J. Rev. 7, 1344-1353 (1993).
50. Niyikiza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. 1, 545-552 (2002).
51. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21(14), 2636-2644 (2003).
52. Rinaldi DA, Kuhn JG, Burris HA et al. A Phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother. Pharmacol. 44, 372-380 (1999).
53. Frenia ML, Long KS. Methotrexate and nonsteroidal anti-inflammatory drug interactions. Ann. Pharmacother. 26, 234-237 (1992).
54. Sweeney CJ, Takimoto CH, Latz JE et al. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer. Clin. Cancer Res. 12, 536-542 (2006).
55. Thodtmann R, Depenbrock H, Dumez H et al. Clinical and pharmacokinetic Phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J. Clin. Oncol. 17, 3009-3016 (1999).
56. Smith G, Amyx H, Boytos CM et al. Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid. Cancer Res. 55, 6117-6125 (1995).
57. Alati T, Worzalla JF, Shih C et al. Augmentation of the therapeutic activity of lometrexol - (6-R)5,10-dideazatetrahydrofolate - by oral folic acid. Cancer Res. 56, 2331-2335 (1996).
58. Bunn P, Paoletti P, Niyikiza C et al. Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc. Am. Soc. Clin. Oncol. 20, (2001) (Abstract 300).
59. Kaye SB. Chemotherapy for ovarian cancer: future potential for new and existing drugs. Am. Soc. Clin. Oncol. Ed. Book 411-415 (2005).
60. Kano Y, Akutsu M, Tsunoda S et al. Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro. Oncol. Res. 16, 85-95 (2006).
61. Tomassetti A, Mangiarotti F, Mazzi M et al. The variant hepatocyte nuclear factor 1 activates the P1 promoter of the human a-folate receptor gene in ovarian carcinoma. Cancer Res. 63, 696-704
62. Hsu DS, Balakumaran BS, Acharya CR et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J. Clin. Oncol. 25(28), 4350-4357 (2007).
63. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: A randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19, 3312-3322 (2001).
64. Lund B, Hansen OP, Theilade K et al. Phase II study of gemcitabine in previously treated ovarian cancer patients. J. Natl Cancer Inst. 86, 1530-1533 (1994).
65. Shapiro JD, Millward MJ, Rischin D et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol. Oncol. 63, 89-93 (1996).
66. Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. 59, 3671-3676 (1999).
67. Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin. Cancer Res. 10, 2936-2943 (2004).
68. Giovannetti E, Mey V, Nannizzi S et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol. Pharmacol. 68, 110-118 (2005).
69. Chen VJ, Bewley JR, Andis SL et al. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRFCEM cells. Br. J. Cancer 78(Suppl. 3), 27-34 (1998).
70. Ma CX, Nair S, Thomas S et al. Randomized Phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 5929-5937 (2005).
71. Abulafia O, Triest WE, Sherer DM. Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 177, 541-547 (1997).
72. Alvarez AA, Krigman HR, Whitaker RS et al. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin. Cancer Res. 5, 587-591 (1999).
73. Goodheart MJ, Ritchie JM, Rose SL et al. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin. Cancer Res. 11, 3733-3742 (2005).
74. Paley PJ, Staskus KA, Gebhard K et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80, 98-106 (1997).
75. Garcia AA, Oza AM, Hirte HW et al. Interim report of a Phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: a California Cancer Consortium Trial. J. Clin. Oncol. 23(Suppl.), 455s, (2005) (Abstract 5000).
76. Cohn DE, Valmadre S, Resnick KE et al. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol. Oncol. 102, 134-139 (2006).
77. Monk BJ, Han E, Josephs-Cowan CA et al. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. 102, 140-144 (2006).
78. Wright JD, Hagemann A, Rader JS et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 107, 83-89 (2006).
79. Burger RA, Sill M, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. J. Clin. Oncol. 23(Suppl.), 457s, (2005) (Abstract 5009).
80. Cannistra SA, Matulonis U, Penson R et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J. Clin. Oncol. 24(Suppl.), 257s, (2006) (Abstract).
81. Weiss GJ, Zeng C, Kelly K et al. Single institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. Clin. Lung Cancer 8, 335-338 (2007).
82. Herbst RS, O'Neill VJ, Fehrenbacher L et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J. Clin. Oncol. 25, 4743-4750 (2007).
83. Patel JD, Hensing TA, Rademaker A et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 27(20), 3284-3289 (2009).Innovative study demonstrating the synergistic activity of bevacizumab when associated with pemetrexed and carboplatin.
84. US FDA: center for drug evaluation and research: Alimta (pemetrexed for injection): label and patient package insert, 5/04 created www.fda.gov/cder/ drug/infopage/alimta/ default.htm